Current Perspectives on Sunitinib Targeted Therapy for Tumors

Karolin Kamel Abdel-Aziz
2011 Journal of Cancer Therapy  
This review highlights therapeutic agents from recent cancer therapeutic trials showing the greatest potential for further clinical use for sunitinib in the near future. In fact, sunitinib is one of multi-tyrosine kinase inhibitors; tyrosine kinases are enzymes, which transfer phosphate groups from ATP to the hydroxyl group of tyrosine residues on signal transduction molecules. Phosphorylation of signal transduction molecules, in turn, induces dramatic changes in tumor growth, including
more » ... , including activation of angiogenesis and DNA synthesis. Therefore, sustain efforts have been directed for developing inhibitors for angiogenesis, which is the marginal process for tumor growth and development through targeting TKs. Almost if not all angiogenesis inhibitors target the vascular endothelial growth factor (VEGF) signaling pathway. Figure 2. The percentage ratio for the application of sunitinib in cancer therapy in different clinical trails.
doi:10.4236/jct.2011.24073 fatcat:5wlj4wwihrbl7da7344qbuigwu